ABSTRACT
A significant decline in the admission to intensive cardiac care unit (ICCU) has been noted in Italy during the COVID-19 outbreak. Previous studies have provided data on clinical features and outcome of these patients, but information is still incomplete. In this multicenter study conducted in six ICCUs, we enrolled consecutive adult patients admitted to ICCU in three specific time intervals: from February 8 to March 9, 2020 [before national lockdown (pre-LD)], from March 10 to April 9, 2020 [during the first period of national lockdown (in-LD)] and from May 18 to June 17, 2020 [soon after the end of all containment measures (after-LD)]. Compared to pre-LD, in-LD was associated with a significant drop in the admission to ICCU for all causes (- 35%) and acute coronary syndrome (ACS; - 49%), with a rebound soon after-LD. The in-LD reduction was greater for women (- 49%) and NSTEMI (- 61%) compared to men (- 28%) and STEMI (- 33%). Length-of-stay, and in-hospital mortality did not show any significant change from to pre-LD to in-LD in the whole population as well as in the ACS group. This study confirms a notable reduction in the admissions to ICCUs from pre-LD to in-LD followed by an increment in the admission rates after-LD. These data strongly suggest that people, particularly women and patients with NSTEMI, are reluctant to seek medical care during lockdown, possibly due to the fear of viral infection. Such a phenomenon, however, was not associated with a rise in mortality among patients who get hospitalization.
Subject(s)
COVID-19/epidemiology , Coronary Care Units , Non-ST Elevated Myocardial Infarction/epidemiology , Patient Admission/trends , Acute Coronary Syndrome/epidemiology , Adult , Aged , COVID-19/therapy , Comorbidity , Female , Humans , Intensive Care Units , Italy/epidemiology , Male , Middle Aged , Non-ST Elevated Myocardial Infarction/therapy , Patient Admission/statistics & numerical data , Risk AssessmentABSTRACT
Coronary artery disease is a major underlying etiology for heart failure. The role of coronary microvascular disease, and endothelial dysfunction, in the pathophysiology of heart failure is poorly appreciated. Endothelial dysfunction, induced by oxidative stress, contributes to the development of heart failure. Alterations of endothelial function and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure with both reduced and preserved ejection fraction. Indeed, an altered endothelium dependent vasodilatation, causing repeated episodes of ischemia/reperfusion, can induce a chronic stunned myocardium with systolic dysfunction and an increased diastolic stiffness with diastolic dysfunction. Moreover, the altered NO-cGMP pathway directly affects myocardial homeostasis. Endothelial dysfunction is associated with worse prognosis and higher rate of cardiovascular events. Potential therapeutic strategies targeting the NO-cGMP pathway in patients with HF will be discussed in this review article. Although clinical data are still inconclusive, the NO-cGMP pathway represents a promising target for therapy.
Subject(s)
Endothelium, Vascular/physiopathology , Heart Failure/physiopathology , Cyclic GMP/metabolism , Endothelium, Vascular/metabolism , Humans , Microcirculation , Muscle, Skeletal/blood supply , Myocardium/pathology , Nitric Oxide/metabolism , Prognosis , Signal Transduction , Ventricular Dysfunction, Left/physiopathologyABSTRACT
Clinical management of acute pulmonary embolism has changed over the years based on new evidence on diagnosis, prognostic stratification and treatment. The increasing availability of computed tomography angiography has made the diagnosis faster and accurate, although with some concern on radiation exposure and potential for overdiagnosis. The efficacy and safety of simple-to-use oral anticoagulant agents acting as selective direct inhibitors of coagulation certainly offer considerable benefits to the patients. However, the appropriate use of these agents is necessary to maintain an optimal risk-benefit ratio. This paper reports answers to ten frequently asked questions in the management of patients with suspected or proven acute pulmonary embolism.